Atrium Therapeutics, Inc.
RNA • Biotechnology
$14.19
▼ -0.41 (-2.81%)
Current price
EarningsLatest report: Mar 31, 2026
WEAK PROFILEWeakConfidence: 32%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$210.91M
Growth
—
Cash Flow
—
Trend
Limited data
Evidence
Manageable debt level · 0.02Healthy liquidity · 6.53Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 14, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:19 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$14.19
Change-2.81%
Market Cap$210.91M
52W Range11.13 - 16.77
Beta0.37
Gross Margin100.00%
Oper. Margin-4.13%
Profit Margin-4.12%
Debt/Eq0.02
Current Ratio6.53
Quick Ratio6.53
Target$25.00
Price$14.19
Change-2.81%
Market Cap$210.91M
52W Range11.13 - 16.77
Beta0.37
Gross Margin100.00%
Oper. Margin-4.13%
Profit Margin-4.12%
Debt/Eq0.02
Current Ratio6.53
Quick Ratio6.53
Target$25.00
Target Upside76.18%
Target Median$25.00
Target Range25.00 - 25.00
Volume101.55K
Avg Volume201.59K
EPS Surprise0.08
Investment DNA
How strong this company looks for long-term investors
33
out of 100
Business Quality
Margins, moat, returns
30/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
69/100
Why this score▼
Manageable debt level · 0.02Healthy liquidity · 6.53Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-08-14
Low
$25.00
Mean
$25.00
Median
$25.00
High
$25.00
🧾
No insider activity
No recent insider transactions available.